Literature DB >> 15879158

Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors.

Wing Leung1, Rekha Iyengar, Brandon Triplett, Victoria Turner, Frederick G Behm, Marti S Holladay, James Houston, Rupert Handgretinger.   

Abstract

The repertoire of killer Ig-like receptors (KIRs) can be determined at the level of DNA, RNA, or surface protein expression for selection of blood stem cell donors. We compared genotyping and phenotyping of the four inhibitory KIRs that are important in transplantation for leukemia in 73 unrelated persons. In 5 (7%) of the 68 individuals in whom the KIR2DL1 gene was present and in 10 (15%) of the 67 in whom KIR3DL1 was present, the corresponding receptor was not expressed by NK cells, as determined by flow cytometry analysis. In contrast, one or both allelic forms of KIR2DL2/KIR2DL3 were expressed by a high proportion of NK cells in all 73 individuals. However if both KIR2DL2 and KIR2DL3 genes were present, KIR2DL3 was preferentially expressed, as transcripts of KIR2DL2 was not detectable by RT-PCR in 42% of these individuals. In total, repertoire assessment for the four KIRs by genotyping vs phenotyping was not in complete agreement in 18 (25%) of the 73 individuals. Furthermore, among the samples that tested positive for the expression of a certain KIR gene, the levels of transcripts and surface expression varied considerably as measured by both real-time quantitative PCR and flow cytometry analysis. Extension of this comparative analysis to include all 12 KIR family members showed that KIR2DL3 and KIR3DL2 were the only genes whose transcripts were consistently detectable. These results caution the use of genotyping alone for donor selection or leukemia-relapse prognostication because some KIRs may be expressed at a very low level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879158     DOI: 10.4049/jimmunol.174.10.6540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Differential RNA expression of KIR alleles.

Authors:  Colum McErlean; Asensio A Gonzalez; Rodat Cunningham; Ashley Meenagh; Tanya Shovlin; Derek Middleton
Journal:  Immunogenetics       Date:  2010-05-08       Impact factor: 2.846

2.  KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia.

Authors:  Brandon Triplett; Rupert Handgretinger; Ching-Hon Pui; Wing Leung
Journal:  Blood       Date:  2006-02-01       Impact factor: 22.113

3.  Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation.

Authors:  Antonio Perez-Martinez; Rekha Iyengar; Kwan Gan; Thirachit Chotsampancharoen; Barbara Rooney; Marti Holladay; Manuel Ramírez; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

4.  A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.

Authors:  Stella M Davies; Robert Iannone; Todd A Alonzo; Yi-Cheng Wang; Robert Gerbing; Sandeep Soni; E Anders Kolb; Soheil Meshinchi; Paul J Orchard; Linda J Burns; Shalini Shenoy; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2019-12-21       Impact factor: 5.742

5.  Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.

Authors:  Rafijul Bari; Piya Rujkijyanont; Erin Sullivan; Guolian Kang; Victoria Turner; Kwan Gan; Wing Leung
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.

Authors:  Jumei Shi; Guido Tricot; Susann Szmania; Nancy Rosen; Tarun K Garg; Priyangi A Malaviarachchi; Amberly Moreno; Bo Dupont; Katharine C Hsu; Lee Ann Baxter-Lowe; Michele Cottler-Fox; John D Shaughnessy; Bart Barlogie; Frits van Rhee
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

7.  Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.

Authors:  Jeffrey E Rubnitz; Patrick Campbell; Yinmei Zhou; John T Sandlund; Sima Jeha; Raul C Ribeiro; Hiroto Inaba; Deepa Bhojwani; Mary V Relling; Scott C Howard; Dario Campana; Ching-Hon Pui
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

8.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Raul C Ribeiro; Stanley Pounds; Barbara Rooney; Teresa Bell; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 9.  New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.

Authors:  M A Pulsipher; A S Wayne; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2014-06-16       Impact factor: 5.483

10.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.